RGTA – Base Matrix Therapy in Corneal Regeneration after Refractive Surgery
Wydanie 1/2018
str. 27 – 28
Autorzy: Katarzyna Jadczyk-Sorek 1,2 , Ewa Mrukwa-Kominek 1,2
1 Klinika Okulistyki Katedry Okulistyki Śląskiego Uniwersytetu Medycznego w Katowicach
Kierownik: prof. dr hab. n. med. Ewa Mrukwa-Kominek
1 Oddział Okulistyki Dorosłych Uniwersyteckiego Centrum Klinicznego im. prof. K. Gibińskiego Śląskiego Uniwersytetu Medycznego w Katowicach
Kierownik: prof. dr hab. n. med. Ewa Mrukwa-Kominek
Summary: Refractive surgery procedures are characterized by relatively high efficacy and low frequency of complications. The most common complications are: corneal haze, glare, „halo” and reduced night vision. The postoperative complications that have a direct impact on the final visual acuity are largely associated with abnormal corneal regeneration.
Currently, in corneal epithelial healing after refractive surgery a new type of matrix therapy – ReGeneraTing Agent (RGTA) which trade name is Cacicol20® is used. Therapy based on the extracellular matrix is a modern, minimally invasive approach in the field of regenerative medicine, which creates an interesting alternative to existing therapy, increasing the quality of the tissue regeneration process, minimizing the risk of postoperative complications and thus improving the quality of life after refractive surgery.